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ABSTRACT
Introduction: Glycated hemoglobin (A1c) and
glycated albumin (GA) are often used as indi-
cators of glycemic control. In this study, we
determined whether prednisolone (PSL)
administration lowers plasma GA.
Methods: We investigated the factors affecting
GA using multivariate analysis in 48 subjects
with connective tissue diseases (CTDs).
Results: Multiple regression analysis of GA
showed that the dose of PSL [b = - 1.36; 95%
confidence interval (CI) - 2.59 to - 0.14;
p = 0.03], age (b = 0.06; 95% CI 0.03–0.09;
p\0.001), body mass index (BMI) (b = - 0.14;
95% CI - 0.28 to - 0.01; p = 0.042), and A1c
(b = 1.4; 95% CI 0.38–2.42; p = 0.008) signifi-
cantly correlated with GA (adjusted R2 = 0.518).
Moreover, GA levels adjusted for age, sex, BMI,
plasma albumin (Alb) and creatinine (Cre), and
A1c in the subjects taking C 5 mg PSL was sig-
nificantly lower than those in those taking
\5 mg PSL. Finally, the dose of PSL (as a con-
tinuous variable) was negatively correlated with
GA adjusted for age, sex, BMI, Alb, Cre, and A1c.
Conclusion: High dose (C 5 mg) PSL reduces
GA concentration more than glycemia.
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INTRODUCTION
Glucocorticoids are widely used for the treat-
ment of diseases such as autoimmune disease
and chronic kidney disease [1, 2]. However,
such treatment predisposes to diabetes, with
odds ratios for new-onset diabetes mellitus
(DM) in patients treated with glucocorticoids
having been shown to be 1.5–2.5 [1, 2]. Steroid-
induced DM is associated with marked post-
prandial hyperglycemia due to peripheral insu-
lin resistance and islet cell dysfunction [1].
Insulin sensitizers, such as thiazolidinediones
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and metformin, are often used as first-line
therapies. However, insulin secretory capacity is
also reduced; therefore, insulin therapy and oral
hypoglycemic drugs may also be used [3]. Fol-
lowing these steps, if glycemic control remains
insufficient, intensive insulin therapy may also
be required after steroid therapy [3]. Early
detection of steroid-induced DM is needed to
prevent insulin therapy [3].
Several indices are now used to evaluate
glycemic control, but glycated hemoglobin A1c
(A1c) is the most frequently used. However, in
specific conditions, such as hemolytic anemia
and hemoglobinopathies, there are discrepan-
cies between actual glycemic control and A1c
concentration [4, 5]. In such instances, mea-
surement of glycated albumin (GA) is recom-
mended [4]. Because albumin (Alb) has a shorter
half-life than hemoglobin, GA reflects the effi-
cacy of glycemic control over a shorter period of
time than A1c [6], and more accurately reflects
postprandial than fasting hyperglycemia [7].
Because early stage steroid-induced DM exhibits
postprandial hyperglycemia with normal fast-
ing glucose levels [1], GA can be an appropriate
indicator of glycemic status in patients with
steroid-induced DM. However, in some previous
studies, glucocorticoid administration has been
shown to lower plasma GA more effectively
than glycemia [8]. Nevertheless, it remains
unclear whether glucocorticoid treatment
reduces plasma GA concentration.
In this study, we determined whether high
dose prednisolone (PSL) affects plasma GA
concentration in patients with connective tis-
sue diseases (CTDs) using multivariate analysis.
The identification of factors affecting GA con-
centration may define contraindications for the
use of GA in subjects undergoing steroid
treatment.
METHODS
Study Subjects
We retrospectively reviewed the medical records
of outpatients with CTDs who had attended our
department at Gifu University Hospital between
April 2009 and June 2016 (Table 1). Forty-eight
subjects were identified and placed into two
groups: those who had been taking\ 5 mg PSL-
equivalent per day, and those who had been
taking C 5 mg PSL-equivalent per day. Subjects
eligible for this study met the following criteria:
(1) age 20–80 years; (2) dose of steroid unchan-
ged within a 3-month period; and (3) HbA1c
concentration changed by B 0.2% over a
2-month period. The exclusion criteria were as
follows: (1) type 1 DM; or (2) presence of
infectious disease, thyroid disease, malignant
tumor, liver cirrhosis, unstable DM, anemia, or
chronic renal disease (estimated glomerular fil-
tration rate \60 ml/min/1.73 mm2, protein-
uria, or hematuria). The study protocol was
approved by the ethics committee of our uni-
versity (Approval No. 28-139, approval date
Table 1 Summary of connective tissue diseases
n5 48
Rheumatoid arthritis 6
Polymyalgia rheumatica 5
Scleroderma 5
Systemic lupus erythematoses 6
Mixed connective tissue disease 2
Dermatomyositis 3
Ankylosing spondylitis 2
Autoimmune pancreatitis 2
Neuromyelitis optica 1
Sjogren syndrome 2
Microscopic polyangitis 1
Pemphigus 2
Sarcoidosis 1
Pemphigoid 1
Interstitial pneumonia 3
Behcet disease 2
Granulomatosis with polyangiitis 1
Polymyositis 2
Psoriasis vulgaris 1
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2016/8/3) and was designed in accordance with
the Declaration of Helsinki. This study did not
involve an intervention, and was retrospective
and observational in nature, and therefore did
not require a trial registration ID.
Measurement of A1c and GA
Plasma A1c was measured using an automated
high-performance liquid chromatography ana-
lyzer (HLC-723-G9; Tosoh Corporation, Tokyo,
Japan) and is presented as a National Glycohe-
moglobin Standardization Program value. GA
concentration was measured using an enzy-
matic method involving albumin-specific pro-
teinase, ketoamine oxidase, and albumin assay
reagent (Lucica GA-L; Asahi Kasei Pharma
Corp., Tokyo, Japan).
Statistical Methods
Using a Monte Carlo simulation, we determined
that 48 patients would be sufficient to detect a
mean reduction of 0.2 in GA per unit of PSL
with an SD of 2.4, 5 in SD of PSL, 82% power,
and an a level of 0.05. Patients with CTDs were
divided into two treatment groups, those who
had been taking \5 mg and those who had
been taking C 5 mg PSL per day. Continuous
variables are represented as median, 25th and
75th percentile. Categorical variables are pre-
sented as numbers and percentages. Normally
distributed clinical characteristics [age, hemo-
globin (Hb), plasma Alb and creatinine (Cre),
and body mass index (BMI)] were compared
using Student’s t test. A multivariable linear
regression model was used to evaluate the rela-
tionship between the dose of PSL (\ 5 mg PSL
or C 5 mg PSL) and GA, with adjustment for
age, sex, BMI, Alb, Cre, and A1c. These factors
were chosen a priori on the basis of their clinical
significance and possible effect on GA. To
evaluate multi-collinearity, the variance infla-
tion factor (VIF) was calculated for each vari-
able. VIF[5 was considered to indicate
collinearity. The reliability of the model was
internally validated using the bootstrap
method. The optimism parameter in a calibra-
tion plot was calculated as the degree of
overfitting, which was estimated using 150 sets
of bootstrap sampling. We also conducted an
analysis to assess the non-linear association
between the dose of PSL as a continuous vari-
able and plasma GA, in which PSL dose was
modeled with the use of restricted cubic splines
to allow for non-linear association. All statistical
analyses were performed using R statistical
software (version 3.5.1; available at http://www.
rproject.org) and the ‘‘rms’’ package.
RESULTS
Subject Characteristics
A total of 48 patients (19 men and 29 women)
were included in the final analysis (Table 2).
Twenty-one patients had been taking \5 mg
PSL per day and 27 had been taking C 5 mg PSL
per day. The characteristics of the patients are
shown in Table 1. Age, gender, BMI, Hb, and
plasma A1c and Cre were similar between the
two groups (Table 2), but the group taking
C 5 mg PSL tended to have lower plasma Alb
(Table 2).
High Dose PSL Lowers Plasma GA Adjusted
for Age, Sex BMI, Alb, and Cre
To determine whether prednisolone use influ-
enced GA concentration, we performed multi-
ple linear regression analysis on plasma GA
(Table 3). The relationship between the dose of
PSL and GA was significant (p = 0.03) after
adjustment for age, sex, BMI, Alb, Cre, and A1c.
The C 5 mg PSL group had a lower GA
[b = -1.36; 95% confidence interval (CI) - 2.59
to - 0.14; Table 3, Fig. 1]. There was an
approximate 0.06 increase in GA per 1 year
increase in age (b = 0.06; 95% CI 0.03–0.09;
p\0.001; Table 2). There was also a trend
towards GA being 0.22 lower in men
(b = - 0.22; 95% CI - 1.80 to 1.37; p = 0.784,
Table 3, Fig. 2). An increase of 1 unit of BMI was
associated with an approximate 0.14 reduction
in GA (b = - 0.14; 95% CI - 0.28 to - 0.01;
p = 0.042, Table 3). In addition, Alb tended to
be about 0.4 higher in patients taking high-
Diabetes Ther (2019) 10:269–276 271
dose PSL (b = 0.4; 95% CI -2.1 to 2.9; p = 0.749;
Table 3) and Cre tended to be about 1.59 higher
(b = 1.59; 95% CI - 3.74 to 6.91; p = 0.55;
Table 3). An increase of 1 unit of A1c was asso-
ciated with an approximate 1.4 increase in GA
(b = 1.4; 95% CI 0.38–2.42; p = 0.008; Table 3).
Box plots of the predicted GA value, adjusted
for covariance, are shown in Fig. 1. The adjusted
R2 was 0.518, suggesting that the regression
model could explain differences in GA well. The
VIFs suggested that collinearity was not present
among the variables (the VIFs were 1.35 for age,
2.30 for sex, 1.09 for BMI, 1.33 for Alb, 2.26 for
Cre, and 1.49 for A1c.) The optimism parameter
for the regression model was 0.09, meaning that
the degree of overfitting was 9.2%; thus, there
was no evidence of overfitting. Finally, the dose
of PSL as a continuous variable was negatively
correlated (p = 0.003) and weakly non-linearly
associated (p = 0.46) with GA adjusted for age,
sex, BMI, Alb, Cre, and A1c (Fig. 2), indicating
that plasma GA decreases as the dose of PSL
increases.
DISCUSSION
In this study, we investigated whether steroid
administration affects GA. Multiple linear
regression analysis showed that PSL dose, age,
BMI, and A1c significantly correlated with
plasma GA. After adjustment of GA for age, sex,
BMI, Cre, and A1c, it was higher in patients
taking 5 mg PSL than in those taking \5 mg
PSL. Therefore, in subjects undergoing high-
dose (C 5 mg) PSL therapy, it is possible that the
use of GA may be associated with a underesti-
mation of the severity of hyperglycemia.
This study is the first to reveal that high-dose
PSL lowers GA, although it was a small retro-
spective study. A previous study reported that
Table 2 Baseline clinical characteristics of 48 subjects
Total (n5 48) PSL < 5 mg (n5 21) PSL ‡ 5 mg (n5 27)
Age 57.5 [43.8–72.0] 62.0 [46.0–70.0] 57.0 [36.5–72.5]
Male sex (%) 19 (39.6) 8 (38.1) 11 (31.2)
BMI 23.38 [20.22–24.48] 23.37 [20.06–26.93] 23.38 [20.43–23.83]
Alb 4.2 [4.0–4.3] 4.2 [4.1–4.4] 4.1 [4.0–4.2]
Cre 0.63 [0.55–0.74] 0.66 [0.59–0.75] 0.60 [0.53–0.73]
HbA1c 5.9 [5.6–6.4] 5.7 [5.5–6.0] 6.0 [5.7–6.6]
Table 3 Multiple linear regression analysis of GA
Coefﬁcient 95% LCI 95% UCI p value
Dose of PSL - 1.36 - 2.59 - 0.14 0.03
Age 0.06 0.03 0.09 \0.001
Male sex (%) - 0.22 - 1.80 1.37 0.784
BMI - 0.14 - 0.28 - 0.01 0.042
ALB 0.40 - 2.10 2.90 0.749
CRE 1.59 - 3.74 6.91 0.55
A1c 1.40 0.38 2.42 0.008
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GA in patients with Cushing’s syndrome is
lower than in patients with type 2 DM [9], and a
patient treated with 20 mg prednisolone has
also been described who exhibited GA-to-A1c
ratios that were persistently lower (1.49–1.80)
than the ratio normally present in type 2 DM
patients (2.5) [8]. It is known that alterations in
albumin concentration can affect GA, and glu-
cocorticoids upregulate both protein synthesis
and degradation, thereby increasing protein
turnover [10]. In fact, plasma albumin in
patients taking C 5 mg PSL was significantly
lower than that in those taking \5 mg PSL.
When it is also considered that plasma GA in
patients with nephrotic syndrome and hyper-
thyroidism is lower than would be expected
according to the degree of glycemic control
[11, 12], it is likely that high-dose PSL causes a
reduction in GA as a result of altered albumin
turnover.
The use of glucocorticoids can been associ-
ated with the development of osteoporosis,
osteonecrosis, cataracts, hyperglycemia, coro-
nary heart disease, and cognitive impairment,
but the minimum dose required to induce these
adverse effects has been shown to be about 5 mg
Fig. 1 Glycated albumin adjusted for age, sex, body mass
index, creatinine, albumin, and glycated hemoglobin A1c is
lower in patients taking C 5 mg prednisolone. Multiple
linear regression analysis of the effect of prednisolone
(PSL) dose on glycated albumin (GA) adjusted for age
57.5, sex = M, BMI 23.38, plasma albumin (Alb) 4.2,
plasma creatinine (Cre) 0.625, and hemoglobin A1c 5.9.
*p\ 0.05. n = 21 and 24 in the\ 5 mg PSL and C 5 mg
PSL groups, respectively
Fig. 2 Correlation between plasma glycated albumin and
prednisolone dose. A multivariable linear regression model
was used to evaluate the associations between dose of
prednisolone (PSL) (as a continuous variable) and glycated
hemoglobin (GA) adjusted for age, sex, body mass index
(BMI), plasma albumin (Alb), plasma creatinine (Cre),
and glycated hemoglobin A1c (A1c). The solid line
indicates the predicted GA after adjustment for age 57.5,
sex = male or female, BMI 23.38, Alb 4.2, Cre 0.625, A1c
5.9. The gray band indicates the 95% conﬁdence interval
for the regression line
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PSL per day [13, 14]. Therefore, high-dose PSL is
often defined as C 5 mg PSL [13, 14]. Moreover,
the incidence of DM in patients taking C 5 mg
PSL was five times higher than in patients taking
\5 mg PSL [15]. Therefore, we divided the
subjects in this study into those taking\5 mg
PSL and those taking C 5 mg PSL. Our data
show that the use of GA as an indicator of gly-
cemic status in patients taking high doses of
steroids may be associated with an underesti-
mation of the severity of hyperglycemia.
It has previously been reported that A1c, age,
and BMI significantly affect plasma GA levels
[16–19]. Because A1c also indicates the severity
of recent glycemia, it is closely correlated with
GA [17, 18], and the relationship has been
described by HbA1c = 0.216 9 GA ? 2.978
[R2 = 0.5882, p\ 0.001] [18]. GA increases with
age from infancy to adulthood and therefore
age-adjusted GA can more accurately reflect
glycemic status [19, 20]. Most obese individuals
are insulin resistant, which can be associated
with postprandial hyperglycemia, which tends
to increase GA rather than A1c [7, 21, 22], such
that, for example, the GA-to-A1c ratio is often
higher in patients with type 1 DM [7, 21].
Moreover, the risk of steroid-induced DM is
greater in individuals with a higher BMI [23].
However, our data show that GA is negatively
correlated with BMI, which is consistent with
many previous reports [24–26]. Finally, other
authors have speculated that greater protein
turnover and inflammation may contribute to
the observed GA levels in obese subjects [26].
Although the mechanism has not been eluci-
dated in this study, A1c, age, and BMI have
been shown to affect GA concentration.
This study had a number of limitations.
Firstly, it was not a randomized study, it was
small, and conducted only in one hospital;
therefore, we are mindful that there is a risk of
selection bias. To further investigate the effects
of PSL dose on GA, a prospective study (such as
a cohort study) is required. Secondly, the range
of A1c concentrations was limited to 5.0–7.5%;
therefore, conclusions regarding GA can only be
drawn for patients with A1c values within this
range. Thirdly, we used A1c as a marker of gly-
cemic control, rather than multiple or contin-
uous peripheral blood glucose measurements,
which can provide a more accurate picture of
glycemic control, but would not be covered by
health insurance in Japan. Finally, we only
studied subjects with connective tissue diseases
and not healthy individuals, for which we
would not have had the opportunity to measure
A1c and GA; therefore, we could not compare
data obtained from diseased subjects with
healthy subjects.
CONCLUSION
We have demonstrated that high doses of PSL,
as well as age, high BMI, and high A1c, are
associated with relatively low GA concentra-
tions compared with the severity of hyper-
glycemia. Thus, when high-dose (C 5 mg) PSL is
administered to patients with CTDs, the use of
GA might be associated with an underestima-
tion of the degree of glycemic control.
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